Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors

Bleeding episodes in hemophiliacs with inhibitors are difficult to control. Staidson protein-0601 (STSP-0601), a specific factor (F)X activator purified from the venom of Daboia russelii siamensis, has been developed. We aimed to investigate the efficacy and safety of STSP-0601 in preclinical and cl...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thrombosis and haemostasis 2023-06, Vol.21 (6), p.1453-1465
Hauptverfasser:	Liu, Wei, Xue, Feng, Fu, Rongfeng, Ding, Bingjie, Li, Mengjuan, Sun, Ting, Chen, Yunfei, Liu, Xiaofan, Ju, Mankai, Dai, Xinyue, Wu, Quanrui, Zhou, Zan, Yu, Jiaojiao, Wang, Xiaomin, Zhu, Qing, Zhou, Hu, Yang, Renchi, Zhang, Lei
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies clinical trial Cysteine Endopeptidases FX activator hemophilia Hemophilia A - diagnosis Hemophilia A - drug therapy Humans inhibitors Neoplasm Proteins preclinical study
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!